ImmuPharma (LON:IMM) Shares Up 11.5% - What's Next?

Key Points

• ImmuPharma's shares surged 11.5% during mid-day trading, reaching a high of GBX 15.15 ($0.20), with a significant trading volume of 41,889,082 shares, up 442% from the usual average.
• The company reported a net margin of 3,519.56% and analysts predict a negative EPS of -339.0000022 for the current fiscal year.
• ImmuPharma specializes in peptide-based therapeutics, with a focus on developing treatments for autoimmune diseases through its lead program, Lupuzor™.

ImmuPharma plc (LON:IMM - Get Free Report) rose 11.5% on Wednesday . The stock traded as high as GBX 15.15 ($0.21) and last traded at GBX 12.40 ($0.17). Approximately 41,889,082 shares were traded during mid-day trading, an increase of 442% from the average daily volume of 7,734,781 shares. The stock had previously closed at GBX 11.13 ($0.15).

ImmuPharma Stock Performance

The stock has a market capitalization of £69.86 million, a price-to-earnings ratio of -1,570.67 and a beta of 1.53. The company has a fifty day simple moving average of GBX 3.12 and a two-hundred day simple moving average of GBX 2.92.

ImmuPharma (LON:IMM - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) EPS for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. As a group, equities analysts anticipate that ImmuPharma plc will post -339.0000022 earnings per share for the current year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.